Zenith Labs Chapter 11
Reorganization plan filing deadline extended 120 days from Sept. 1 to Dec. 30. Generics company noted at the Aug. 29 hearing in Newark Federal Court that a further extension may be required. Court also extended Zenith's right to use collateral, subject to the requirement that monthly interest payments be made to the five-bank consortium. Zenith filed for Chapter 11 on May 4.
You may also be interested in...
The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.
The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.
The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.